Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SE Asia Government Leaders to Discuss Move Towards Self-Sufficiency in Plasma Fractionation

Published: Thursday, August 29, 2013
Last Updated: Thursday, August 29, 2013
Bookmark and Share
Self-sufficiency is important to reduce costs, prevent blood shortages and meet the transfusion requirements of patients.

At the 63rd World Health Assembly, WHO member nations were encouraged "to take all the necessary steps to establish, implement and support nationally-coordinated, efficiently managed and sustainable blood and plasma programmes according to availability of resources, with the aim of achieving self-sufficiency".

Currently, excluding China, plasma fractionation plants are only available in the US, Europe, Japan, South Korea and Australia. Most of these fractionators are focused on the European and US markets and only supply Asia with excess product. Although a few high development index (HDI) countries in the Asia Pacific region have sufficient access to a broad portfolio of plasma products through domestic or contract plasma fractionation programmes, the volume of plasma fractionated in the region is too low to meet the needs, resulting in high prices.

Recognizing the importance of self-sufficiency to reduce costs, prevent blood shortages and meet the transfusion requirements of patients, a number of South-East Asian countries are moving towards setting up domestic fractionation plants.

Earlier this month, Malaysia’s Strovi Tel Sdn Bhd announced the construction of the country’s first fractionation plant through a partnership with LFB - Laboratoire francais du Fractonnement of des Biotechnologies – also stating its plans to further expand its business eventually into the South-East Asian and Middle East markets. Thailand’s Thai Red Cross Society (TRCS) also announced a partnership with Korea’s Green Cross, in January 2013, to design and construct a blood plasma separating facility in the Chon Buri province. While Malaysia and Thailand make headway, countries like Indonesia, Phillippines and Singapore are not far behind from self-sustenance.

At the upcoming Bioplasma World Asia 2013 gathering (co-located with Asia’s most prominent bloodborne Pathogen workshop) taking place on 3-5 September 2013 in Bali, health representatives from these and many other Asian more countries, will get together with international plasma fractionators, blood establishments, and technology providers  to explore opportunities and viable partnerships to meet the persistently rising demand of the Asian blood and bioplasma products market.

Some of the confirmed fractionators and government bodies attending this event include Central Blood Collection, Egypt, Indonesian Red Cross, Indonesia, Ministry Of Health, Kuwait, Ministry Of Health, Phillippines, National Institute of Hematology and Blood Transfusion, Vietnam, National Institute of Biologicals, India, Baxter Healthcare, Austria, Greencross, Korea, Blood Product Research Organization, Japan, CSL Behring, Australia, Cordlife Blood Center, Singapore, Red Crescent Society, Brunei, Red Crescent Society, Malaysia, LFB,  France, and Prime Biologics, Singapore.

Technology providers like Sartorius Stedim Biotech, Haemonetics Corporation, Asahi Kasei Medical Co. Ltd, Merck Millipore, Novartis, Nigale, GFE Blut, Dometic, ProMetic, Fresenius Kabi, Neste Jacobs, Boccard, Roche, Abbott, Cerus, will also be present.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!